Objectives: Schizophrenia (SCZ) is characterized by significant impairments in perception and cognitive flexibility. Making accurate plans for therapy demands a deeper comprehension of the brain mechanisms behind these disorders. The purpose of our investigation is to analyze the protective effects of papaverine, a phosphodiesterase-10 inhibitor, on ketamine-induced SCZ -like behavioral and...
BackgroundDelirium is a common and serious complication in critically ill and surgical patients, associated with increased morbidity, prolonged hospitalization, and long-term cognitive impairment. Ketamine and esketamine have been proposed as potential protective agents due to their anti-inflammatory, analgesic, and NMDA receptor-blocking properties.MethodsWe conducted a systematic review and...
Background: Ketamine, a dissociative anaesthetic and non-competitive NMDA receptor antagonist, has legitimate medical applications. However, rising illicit use across the United Kingdom (UK) has been accompanied by growing reports of toxicity, dependence, and deaths. These have led to renewed policy discussions. Rationale and Aim: Previous national studies have reported ketamine-related deaths...
Ketamine misuse is an increasing public health concern among adolescents in the United Kingdom, with initiation reported as early as 14 years of age and a rapidly rising demand for drug and alcohol support services. Chronic ketamine misuse is associated with significant urological sequelae, including ketamine-induced uropathy, a condition increasingly encountered within paediatric and...
Short-acting ketamine-related scaffold design remains an important medicinal-chemistry problem, but computational studies require conservative interpretation until receptor, enzymatic, and pharmacokinetic validation is available. S-ketamine, S-Remiketamine, and R1-R20 analogues were assessed using ligand curation, NMDA receptor docking, cross-target docking, explicit-solvent molecular dynamics,...
Autism Spectrum Disorder (ASD) is a neurodevelopmental condition marked by persistent social communication deficits and repetitive behaviors, with communication abilities ranging from nonverbal to verbally fluent yet socially impaired. These deficits, linked to disrupted neural connectivity in regions like the posterior superior temporal sulcus (pSTS), reward circuits, and dorsal/ventral speech...
BACKGROUND: Treatment-resistant depression (TRD) affects approximately one-third of patients with major depressive disorder and represents a critical clinical challenge. Esketamine (S-ketamine, Spravato), approved by FDA and EMA since 2019, and psychedelic-assisted therapies (psilocybin, MDMA) share a pharmacological feature unique among approved psychiatric treatments: they induce altered...
A BSTRACT Major depressive disorder is commonly associated with suicidal ideation, while conventional antidepressants have a delayed onset of action. Ketamine has emerged as a rapid-acting antidepressant with potential anti-suicidal effects. This retrospective case series evaluated the effectiveness and tolerability of intravenous ketamine in patients with major depressive disorder and active...
Ketamine therapy is effective in alleviating symptoms of psychiatric disorders such as depression and anxiety; however, its increasing recreational use raises concerns about potential abuse. Hericium erinaceus mycelium, which contains the bioactive compound erinacine A, has shown promise in promoting brain health. This study investigated whether H. erinaceus mycelium and erinacine A could...
Introduction: Obsessive-compulsive disorder (OCD) is a chronic psychiatric condition that frequently presents with comorbid depressive disorders. For patients exhibiting treatment-refractory OCD and concurrent depressive disorder(s), there is growing clinical interest in the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist ketamine as a rapid-acting intervention. This case report...